Cellectar says tumors shrank as much as 90 percent in early trials of its lead cancer drug

A study will begin this fall on the drug’s impact on pediatric tumors, and in 2019, in a collaboration with the UW-Madison’s Carbone Cancer Center, it will be tested along with radiation for treating recurring head and neck cancer.